Wealth Enhancement Advisory Services’s Agios Pharmaceuticals AGIO Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$740K	Buy	+17,959	New	+$545K	﹤0.01%	2325

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Wealth Enhancement Advisory Services's AGIO Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Agios Pharmaceuticals (AGIO) in Q2 2026: 17,959 shares worth $740K. The stake represents ﹤0.01% of the portfolio and ranks #2325 among its holdings.

238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

Wealth Enhancement Advisory Services held 17,959 shares of Agios Pharmaceuticals worth $740K as of Q2 2026.
Agios Pharmaceuticals was a new Wealth Enhancement Advisory Services position in Q2 2026.
Agios Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2325 holding.
238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.